Malaria drug may boost leukemia treatment in new trial
NCT ID NCT07022743
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 26 times
Summary
This study tests whether adding artesunate (a malaria drug) to the standard leukemia medicine imatinib can improve outcomes for people with chronic myeloid leukemia (CML). About 75 adults with newly diagnosed or poorly responding CML will receive either imatinib alone or imatinib plus artesunate. The goal is to see if the combination leads to better cancer control and deeper remission without major side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife
Ile-Ife, Osun State, 3408, Nigeria
Conditions
Explore the condition pages connected to this study.